Usefulness of change to anagliptin from other DPP-4 inhibitors in patients with uncontroled LDL-cholesterol

Usefulness of change to anagliptin from other DPP-4 inhibitors in patients with uncontroled LDL-cholesterol - Anagliptin and LDL-cholesterol

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012329

Enrollment

Registered

2013-12-01

Start date

2013-12-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

typr 2 diabetes hypercholesterolemia

Interventions

anagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: in use of a DPP-4 inhibitor other than anagliptin LDL-cholesterol >= 120mg/dl

Exclusion criteria

Exclusion criteria: HbA1c > 8% LDL-cholesterol >= 160mg/dl history of colonary disease

Design outcomes

Primary

Measure	Time frame
LDL-cholesterol concentration	—

Countries

Japan

Contacts

Public ContactKen Ebihara

Kyoto University Hospital Institute for Advancement of Clinical and Translational Science

kebihara@kuhp.kyoto-u.ac.jp075075103173

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026